Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Spain

European Research Council grant · Running

TROPOSplice Bioinspired Modulation of Cardiac Troponin I Splicing to Treat Diastolic Dysfunction

Coordinator
Centro Nacional De Investigaciones Cardiovasculares Carlos Iii (f.s.p.), Spain
Runs
1 February 2027 to 31 January 2032
Status
Running
EU funding
€1.5m
Total cost
€1.5m
Partners
1 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101300314

What the project is doing

In the project's own words, from its summary on CORDIS.

Diastolic dysfunction, i.e. impaired cardiac relaxation and filling, is a hallmark shared by various heart diseases, including hypertrophic cardiomyopathy (HCM) and heart failure with preserved ejection fraction (HFpEF). It is often driven by excessive calcium sensitivity of the cardiac myofilaments, and in HCM and HFpEF alike, is associated with disrupted adrenergic signalling, culminating in reduced responsiveness of the heart to adrenaline.

In the healthy heart, adrenergic stimulation normally decreases myofilament calcium sensitivity via phosphorylation of the N-terminus of cardiac troponin I (cTnI). Remarkably, this effect can also be mimicked by truncation of the cTnI N-terminus. We recently discovered that small mammals such as bats and shrews, which have extraordinarily high cardiac demands, have evolved to skip the exon encoding the cTnI N-terminus via alternative splicing or genomic deletion.

This creates a permanently desensitized cTnI, bypassing the need for sustained β-adrenergic signalling. While alternative splicing of cTnI does not naturally occur in humans or most other mammals, it could be therapeutically induced using antisense oligonucleotides (AONs) in order to increase myocardial relaxation rate. TROPOSplice aims to develop a splice-switching antisense therapeutic that induces cTnI exon 3 skipping to mimic the myofilament desensitizing effect of adrenaline, leveraging a bioinspired strategy “from bats to bedside”.

Crucially, as this approach acts downstream of adrenergic receptors, it is compatible with mainstay cardiovascular treatments such as beta-blockers. We will adopt a translational approach, from cultured cardiomyocytes to in vivo mouse models, to optimise AON design and delivery and to investigate the physiological effects of induced cTnI exon 3 skipping. This project offers a novel, evolution-guided therapeutic strategy to treat diastolic dysfunction and could ultimately benefit patients with HCM, HFpEF, and related heart conditions.

Topics

Who is involved

OrganisationCityCountryRole
Centro Nacional De Investigaciones Cardiovasculares Carlos Iii (f.s.p.)MadridSpainCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI